Infinity to Present at Two Upcoming Conferences

Monday, March 26, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

CAMBRIDGE, Mass., March 26, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology

company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be presenting at the following two upcoming conferences:

Needham & Company Annual Healthcare Conference:

Lawrence Bloch, M.D., J.D., Infinity's President, will present at Needham & Company's 17th Annual Healthcare Conference on Tuesday, March 27, 2018, at 11:00 a.m. ET at the Westin NY Grand Central Hotel in New York, NY. A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

8th Annual Cancer and Immunotherapy Conference: Jeffery Kutok, M.D., Ph.D., Infinity's Chief Scientific Officer, will present during the "The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on Suppressive Myeloid Cells," session at the 8th Annual Cancer and Immunotherapy Conference hosted by William Blair & Company and MaidStone Life Sciences on April 5, 2018, at 10:40 a.m. ET at the Apella Event Space Alexandria Center, New York, NY. 

About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Contact:Stephanie Ascher, Stern Investor Relations, Inc.212-362-1200 or Stephanie@sternir.com

Cision View original content:http://www.prnewswire.com/news-releases/infinity-to-present-at-two-upcoming-conferences-300619141.html

SOURCE Infinity Pharmaceuticals, Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store